• Nordic Bioscience A/S, of Copenhagen, Denmark, and Unigene Laboratories Inc., of Boonton, N.J., disclosed the preliminary selection of a lead compound for Type II diabetes under the firms' joint development vehicle (JDV).
To continue reading subscribe now to BioWorld International
